Select Page

Démence

Pour plus d’informations sur les essais cliniques sur l’Alzheimer ou relié à la démence, veuillez contacter Salma Khalil
Chercheur principal: Dr Simon Ducharme
 

Études actuelles en recrutement

Initiative sur la démence frontotemporale génétique 2

De genfi.org.uk. Malheureusement, les informations ne sont disponibles qu’en anglais. Pour plus d’informations en français, veuillez contacter Salma Khalil.

The aim of the study is to understand more about genetic FTD, particularly in those who have mutations in the progranulin (GRN), microtubule-associated protein tau (MAPT) and chromosome 9 open reading frame 72 (C9ORF72) genes. There are now promising avenues for treatment of these disorders but we still do not know when drugs should be started or how we should measure the response to treatment.

GENFI investigates both people who have developed symptoms and also people who have a risk of developing symptoms in the future because they carry an abnormal genetic mutation. By studying these individuals who are destined to develop the disease later in life we can understand the development from the very earliest changes. The key objectives of GENFI are therefore to develop markers which help identify the disease at its earliest stage as well as markers that allow the progression of the disease to be tracked.

The eventual aim will be to use these markers in future clinical trials of drugs in genetic FTD.

Plus d’information

Étude clinique de phase 2 sur l’ocytocine intranasale pour la démence fronto-temporale (FOXY)

De clinicaltrials.gov. Malheureusement, les informations ne sont disponibles qu’en anglais. Pour plus d’informations en français, veuillez contacter Salma Khalil.

The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick’s disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.

Plus d’information

Étude évaluant la tolérabilité, la pharmacocinétique et l’efficacité de MP-101 comme traitement de patients atteints de psychose et/ou faisant preuve d’agitation et d’agressivité liées à la démence

De clinicaltrials.gov. Malheureusement, les informations ne sont disponibles qu’en anglais. Pour plus d’informations en français, veuillez contacter Salma Khalil.

A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

Plus d’information

Études actives (ne recrutent pas)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer’s Disease

De clinicaltrials.gov. Malheureusement, les informations ne sont disponibles qu’en anglais. Pour plus d’informations en français, veuillez contacter Salma Khalil.
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer’s Disease

Plus d’information

Étude de phase III évaluant l’innocuité et l’efficacité de l’ALZT-OP1 chez des sujets présentant une évidence de la maladie d’Alzheimer de stade précoce

De clinicaltrials.gov. Malheureusement, les informations ne sont disponibles qu’en anglais. Pour plus d’informations en français, veuillez contacter Salma Khalil.
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer’s disease (AD).

Plus d’information